Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer.
Breast cancer
Secondary malignancy
Stem cell transplantation
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
29
03
2022
accepted:
08
06
2022
pubmed:
3
7
2022
medline:
20
7
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
To compare the outcome of allogeneic stem cell transplantation for myeloid malignancies in breast cancer survivors to a contemporaneous control group. Medical records of all patients with a history of breast cancer who received allogeneic stem cell transplants at a single, tertiary referral Comprehensive Cancer Center between 2002 and 2019 were reviewed. Transplant outcomes were compared to 289 control patients without a history of breast cancer from the same time period. Main outcomes included survival, disease-free survival, non-relapse mortality, relapse or progression of hematologic malignancy, and incidence of recurrent breast cancer after hematopoietic cell transplantation. Comparisons between women with a history of breast cancer and controls utilized propensity score weighting to balance patient characteristics. Forty women, ages 30-74 years, with a history of breast cancer received an allogeneic hematopoietic cell transplant for a hematologic malignancy between December 2002 and February 2019. Twelve of the 40 patients are alive with a median survival of 7.4 years (range, 1.9-16.8 years). None of the patients had evidence of recurrent breast cancer prior to death or date of last contact. In multivariable Cox models, all transplant outcomes were similar between the patients and the control group with hematopoietic cell transplant comorbidity score as the most important confounding factor for adjustment in these models. A history of treated breast cancer should not exclude patients from consideration for allogeneic hematopoietic cell transplantation.
Identifiants
pubmed: 35779160
doi: 10.1007/s10549-022-06658-5
pii: 10.1007/s10549-022-06658-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-516Subventions
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438–451
doi: 10.3322/caac.21583
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975–2017. In.: National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/ , based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
Lavey RS, Eby NL, Prosnitz LR (1990) Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer 66(5):874–881
doi: 10.1002/1097-0142(19900901)66:5<874::AID-CNCR2820660511>3.0.CO;2-6
Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326(26):1745–1751
doi: 10.1056/NEJM199206253262605
Obedian E, Fischer DB, Haffty BG (2000) Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18(12):2406–2412
doi: 10.1200/JCO.2000.18.12.2406
Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J, Powles R, Ashley S, Kuan A, Powles T (2000) Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 83(1):91–94
doi: 10.1054/bjoc.2000.1196
Smith RE, Bryant J, DeCillis A, Anderson S (2003) National Surgical Adjuvant B, Bowel Project E: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21(7):1195–1204
doi: 10.1200/JCO.2003.03.114
Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R et al (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23(18):4179–4191
doi: 10.1200/JCO.2005.05.029
Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH (2007) Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25(25):3871–3876
doi: 10.1200/JCO.2007.12.0832
Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A (2008) Institut curie breast cancer study G: second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98(5):870–874
doi: 10.1038/sj.bjc.6604241
Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A (2007) Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys 68(2):359–363
doi: 10.1016/j.ijrobp.2006.12.011
Karp JEBA, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, et al (2012) Myelodysplastic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. In: Paper presented at the American Association of Cancer Research. https://cancerres.aacrjournals.org/content/72/24_Supplement/S3-5
Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK (2017) Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast 35:122–129
doi: 10.1016/j.breast.2017.07.004
Bazire L, De Rycke Y, Asselain B, Fourquet A, Kirova YM (2017) Risks of second malignancies after breast cancer treatment: long-term results. Cancer Radiother 21(1):10–15
doi: 10.1016/j.canrad.2016.07.101
Mayer EL (2013) Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol 2013:9–14
doi: 10.14694/EdBook_AM.2013.33.9
Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, Woodle ES (2009) De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 87(9):1347–1359
doi: 10.1097/TP.0b013e3181a238f6
Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE (1978) The analysis of failure times in the presence of competing risks. Biometrics 34(4):541–554
doi: 10.2307/2530374
Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11(5):550–560
doi: 10.1097/00001648-200009000-00011
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846
doi: 10.1056/NEJMoa1701830
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447
doi: 10.1182/blood-2016-08-733196
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628–1633
doi: 10.1016/j.bbmt.2009.07.004
Why, When and Where to Report Conditioning Drugs [ https://www.cibmtr.org/Meetings/Materials/CRPDMC/Pages/2015Index.aspx ]. Accessed 11 Feb 2021
AlBugami M, Kiberd B (2014) Malignancies: pre and post transplantation strategies. Transplant Rev (Orlando) 28(2):76–83
doi: 10.1016/j.trre.2013.12.002
Rossi AP, Klein CL (2019) Posttransplant Malignancy. Surg Clin North Am 99(1):49–64
doi: 10.1016/j.suc.2018.09.004
Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI et al (2012) New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) 26(4):261–279
doi: 10.1016/j.trre.2012.07.001
Wong G, Au E, Badve SV, Lim WH (2017) Breast cancer and transplantation. Am J Transplant 17(9):2243–2253
doi: 10.1111/ajt.14368
Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR (2007) Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 7(9):2140–2151
doi: 10.1111/j.1600-6143.2007.01908.x
Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE (2006) Cancer incidence before and after kidney transplantation. JAMA 296(23):2823–2831
doi: 10.1001/jama.296.23.2823
Swerdlow SCE, Harris NL et al (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised, 4th edn. International Agency for Research on Cancer IARC, Lyon
Lazarus G, Audrey J, Iskandar AWB (2019) Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. Oncol Rev 13(2):425
doi: 10.4081/oncol.2019.425
Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M et al (2020) PELICAN-IPC 2015–016/Oncodistinct-003: a prospective, multicenter, open-label, randomized, non-comparative, phase ii study of pembrolizumab in combination with neo adjuvant EC-paclitaxel regimen in HER2-negative inflammatory breast cancer. Front Oncol 10:575978
doi: 10.3389/fonc.2020.575978
Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821
doi: 10.1056/NEJMoa1910549
Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P et al (2021) Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol 39(22):2443–2451
doi: 10.1200/JCO.20.02923
Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94–99
doi: 10.1016/j.bbmt.2018.08.028
Soiffer RJ, Davids MS, Chen YB (2018) Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood 131(10):1073–1080
doi: 10.1182/blood-2017-10-752154